

Radiogenic risks of CLL – new evidence and a path for moving forward

Lydia B. Zablotska, MD, PhD

University of California, San Francisco, USA

Abstract

One of the biggest conundrums of radiation epidemiology is whether chronic lymphocytic leukemia (CLL) is radiogenic. The radiogenic risks of CLL have an important public health implication, as it is the most common adult leukemia in the Western hemisphere (~30% of all leukemias in adults over 50.¹) It has been known, since the early 1950's from the Japanese atomic bomb (A-bomb) survivors' study, that radiation exposure may induce most types of leukemia. However, it generally has been accepted that radiation does not induce CLL,^{2,3} or closely allied small lymphocytic subtype of non-Hodgkin lymphoma (NHL).^{3,4} This decision was mainly based on the first 40-years of follow-up of A-bomb survivors.⁵ However, the most-recent report based on 55 years of follow-up showed a significant linear radiation dose-response.⁶ It now seems clear that the major reason for the previous negative findings with regards to radiogenicity of CLL in A-bomb survivors was, most likely, due to very low incidence of CLL in the Japanese population (2-3% of all leukemia cases^{7,8}).

Until recently, the majority of epidemiological studies of radiation-exposed populations, whether from occupational,⁹ environmental⁴ or therapeutic exposures,¹⁰⁻¹² also reported no excess of CLL or NHL. In a reversal of previous findings, recent cancer incidence studies from our group¹³⁻¹⁵ and other incidence studies of occupationally exposed radiation workers¹⁶⁻²⁰ reported significantly increased radiation risks of CLL. There is now an emerging consensus on CLL radiogenicity,²¹⁻²³ but the magnitude of risks remains unknown. We have also come to understand that mortality-based studies could underestimate, possibly substantially, the occurrence of CLL due to its benign clinical course.^{24,25}

The emergence of CLL as a radiation-induced disease has raised questions as to whether these cases demonstrate any unusual clinical or genetic characteristics that might differ from idiopathic CLL. We recently examined associations between bone marrow radiation doses from the Chernobyl accident and clinical manifestations of the CLL which had developed in the cleanup workers.²⁶ We observed that higher radiation doses and younger age at first exposure to radiation during Chernobyl cleanup work were associated with significantly shorter survival. Latent period was not associated with bone marrow radiation dose, stage of disease, chemotherapy treatment or any other clinical characteristics. In our study, the median latent period was 14 years and the median age at diagnosis was 57 years compared to the median age at diagnosis in the US of 72 years.²⁷

Our group has initiated a number of genetic studies to characterize genetic complexity underlying radiogenic CLL. By comparing CLL in Chernobyl cleanup workers with CLL in males of comparable age from the general population of Ukraine unexposed to radiation, we will be able to assess somatically acquired genetic abnormalities and significantly affected pathways underlying radiogenic CLL in Chernobyl cleanup workers. Targeted sequencing using UCSF 500 Cancer Genes Sequencing Panel will identify acquired somatic mutations and characterize genetic complexity underlying radiogenic CLL.

In this presentation we will summarize the evidence to date on radiogenic risks of CLL and discuss paths for moving forward. In particular, additional clinical and genetic studies are necessary to evaluate the finding of progressively poorer survival with increasing bone marrow radiation dose to exclude effects of chance and unmeasured risk factors. Future large incidence studies are needed to characterize risks of low-dose radiation exposures²⁸ and to examine whether protracted and acute exposures have similar leukemogenic risks. Additional studies are necessary to better understand the differences between studies based on Cancer Registry data and on active case ascertainment.

References

1. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. The clinical and epidemiological burden of chronic lymphocytic leukaemia. *Eur J Cancer Care (Engl)*. 2004;13(3):279-87. PMID: 15196232.
2. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). 2000 Report to the General Assembly, with Scientific Annexes. Volume II: Effects. New York: United Nations Scientific Committee on the Effects of Atomic Radiation, 2000.
3. National Research Council (NRC). Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. Health risks from exposure to low levels of ionizing radiation. BEIR VII Phase 2. Washington, DC: NRC, National Academies Press, 2006.
4. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). 2006 Report to the General Assembly with Scientific Annexes. Volume I. Annex A: Epidemiological studies of radiation and cancer. New York: UNSCEAR, 2008.
5. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. *Radiat Res*. 1994;137(2 Suppl):S68-97. PMID: 8127953.
6. Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The Incidence of Leukemia, Lymphoma and Multiple Myeloma among Atomic Bomb Survivors: 1950-2001. *Radiat Res*. 2013;179(3):361-82. PMID: 23398354.
7. Finch SC, Hoshino T, Itoga T, Ichimaru M, Ingram RH, Jr. Chronic lymphocytic leukemia in Hiroshima and Nagasaki, Japan. *Blood*. 1969;33(1):79-86. PMID: 5818236.
8. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. *Jpn J Clin Oncol*. 2013;43(3):328-36. PMID: 23296772.
9. Vrijheid M, Cardis E, Ashmore P, Auvinen A, Gilbert E, Habib RR, et al. Ionizing radiation and risk of chronic lymphocytic leukemia in the 15-country study of nuclear industry workers. *Radiat Res*. 2008;170(5):661-5. PMID: 18959468.
10. Boice JD, Jr., Blettner M, Kleinerman RA, Stovall M, Moloney WC, Engholm G, et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. *J Natl Cancer Inst*. 1987;79(6):1295-311. PMID: 3480381.
11. Curtis RE, Boice JD, Jr., Stovall M, Bernstein L, Holowaty E, Karjalainen S, et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. *J Natl Cancer Inst*. 1994;86(17):1315-24. PMID: 8064889.
12. Damber L, Larsson LG, Johansson L, Norin T. A cohort study with regard to the risk of haematological malignancies in patients treated with x-rays for benign lesions in the locomotor system. I. Epidemiological analyses. *Acta Oncol*. 1995;34(6):713-9. PMID: 7576736.
13. Romanenko A, Finch S, Hatch M, Lubin JH, Bebesko VG, Bazyka DA, et al. The Ukrainian-American study of leukemia and related disorders among Chernobyl cleanup workers from Ukraine: III. Radiation risks. *Radiat Res*. 2008;170(6):711-20. PMID: 19138038.
14. Zablotska LB, Bazyka D, Lubin JH, Gudzenko N, Little MP, Hatch M, et al. Radiation and the risk of chronic lymphocytic and other leukemias among Chernobyl cleanup workers. *Environ Health Perspect*. 2013;121(1):59-65. PMID: 23553431.

15. Zablotska LB, Lane RS, Frost SE, Thompson PA. Leukemia, lymphoma and multiple myeloma mortality (1950-1999) and incidence (1969-1999) in the Eldorado uranium workers cohort. *Environ Res.* 2014;130C:43-50. PMID: 24583244.
16. Kesminiene A, Evrard AS, Ivanov VK, Malakhova IV, Kurtinaitis J, Stengrevics A, et al. Risk of hematological malignancies among Chernobyl liquidators. *Radiat Res.* 2008;170(6):721-35. PMID: 2904977.
17. Mohner M, Gellissen J, Marsh JW, Gregoratto D. Occupational and diagnostic exposure to ionizing radiation and leukemia risk among German uranium miners. *Health Phys.* 2010;99(3):314-21. PMID: 20699692.
18. Rericha V, Kulich M, Rericha R, Shore DL, Sandler DP. Incidence of leukemia, lymphoma, and multiple myeloma in Czech uranium miners: a case-cohort study. *Environ Health Perspect.* 2006;114(6):818-22. PMID: 16759978.
19. Sigurdson AJ, Doody MM, Rao RS, Freedman DM, Alexander BH, Hauptmann M, et al. Cancer incidence in the US radiologic technologists health study, 1983-1998. *Cancer.* 2003;97(12):3080-9. PMID: 12784345.
20. Pukkala E, Aspholm R, Auvinen A, Eliasch H, Gundestrup M, Haldorsen T, et al. Cancer incidence among 10,211 airline pilots: a Nordic study. *Aviat Space Environ Med.* 2003;74(7):699-706. PMID: 12862322.
21. Linet MS, Schubauer-Berigan MK, Weisenburger DD, Richardson DB, Landgren O, Blair A, et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. *Br J Haematol.* 2007;139(5):672-86. PMID: 18021081.
22. Silver SR, Hiratzka SL, Schubauer-Berigan MK, Daniels RD. Chronic lymphocytic leukemia radiogenicity: a systematic review. *Cancer Causes Control.* 2007;18(10):1077-93. PMID: 17694421.
23. Hamblin TJ. Have we been wrong about ionizing radiation and chronic lymphocytic leukemia? *Leuk Res.* 2008;32(4):523-5. PMID: 17915317.
24. Finch SC, Linet MS. Chronic leukaemias. *Baillieres Clin Haematol.* 1992;5(1):27-56. PMID: 1350742.
25. Richardson DB, Wing S, Schroeder J, Schmitz-Feuerhake I, Hoffmann W. Ionizing radiation and chronic lymphocytic leukemia. *Environ Health Perspect.* 2005;113(1):1-5. PMID: 15626639.
26. Finch SC, Dyagil I, Reiss RF, Gudzenko N, Babkina N, Lyubarets T, et al. Clinical characteristics of chronic lymphocytic leukemia occurring in chornobyl cleanup workers. *Hematol Oncol.* 2016;1002/hon.2278. PMID: 26806761.
27. Howlander N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Accessed on: April 15, 2015. Available from: http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted April 2014.
28. Schubauer-Berigan MK, Daniels RD, Fleming DA, Markey AM, Couch JR, Ahrenholz SH, et al. Chronic lymphocytic leukaemia and radiation: findings among workers at five US nuclear facilities and a review of the recent literature. *Br J Haematol.* 2007;139(5):799-808. PMID: 17922878.